Long-term phase 3 trial in 350 men with biochemical recurrence after prostatectomy: 70 Gy vs 64 Gy salvage radiotherapy did not improve freedom from biochemical progression (median 8.7 vs 8.7 yr; HR 1.03) but raised late GI toxicity.
RCTn = 350
Ghadjar et al. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial